Skip to main content
Funded Studies

David Isaac Finkelstein, PhD

Professor, Head of Parkinson’s Disease Laboratory at Florey Institute for Neuroscience and Mental Health

Location: Melbourne VIC Australia

David Finkelstein has long standing interests in the physiological control of movement and age-related neurodegenerative disorders. He has extensive experience in Parkinson’s disease and Alzheimer’s disease, with a particular focus on developing novel therapeutic avenues for the treatment of Parkinson’s disease. His primary expertise is in pre-clinical assessment of new compounds in animal disease models and has been engaged as a consultant to a number of large international pharmaceutical companies and small biotech companies supporting the development of new compounds to slow the progression of neurodegeneration. In collaboration with industry, he led the development of a novel lead compound for Parkinson’s disease which recently completed successful phase 1 clinical testing. He is a former board Chair of Parkinson’s Victoria and is currently a board director and head of its research committee. He is Head of the Parkinson’s Disease Laboratory at the Florey institute of Neuroscience, Melbourne.

Associated Grants

  • Brain-penetrating Antisense Oligonucleotide to Down-regulate Alpha-synuclein


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.